<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mellbin, Linda</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Diabetes and the Heart</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-33</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the therapeutic challenges that are associated with the combination of coronary artery disease (CAD) and diabetes mellitus. The link between CAD and dysglycemia is that the release of stress hormones and peptides due to a myocardial infarction is associated with insulin resistance and increased glucose or free fatty acid levels.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>